Merck Partners with Medisafe to Help Improve Medication Adherence for Cardiometabolic Patients

MerckMerck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication intake and adhere to prescribed treatment regimens. In the countries of scope Merck patients will have access to a customized version of Medisafe's mobile platform that could combine reminders, motivation and support systems, targeted content, coupons and interventions in their local language.

"This is an extremely important step towards realizing our vision of supporting patients with comprehensive, integrated, value-added services that look beyond medicines to improve treatment outcomes. We are confident that offering such a solution to our patients has the potential to significantly improve medication adherence by giving patients and carers the tools to organize, understand and manage their medications," said Simon Sturge, Chief Operating Officer at Merck's Biopharma business.

Medisafe is a leading medication management and adherence solution co-owned by M Ventures, which has been named top app for medication management by November 2017 IQVIA (Quintiles IMS) report. It has received endorsements from the American Pharmacy Association, Journal of Medical Internet Research (JMIR), and Ranked Health. Medisafe has already delivered high rates of adherence across multiple disease areas, and recorded significant improvements - notably, 86% of Stage 2 hypertensive users reduced their risk category to Stage 1 or below.(1)

This digital solution will complement Merck’s current offering of Primary Care medicines for cardiometabolic conditions, which includes treatments for type 2 diabetes, thyroid disorders, and cardiovascular diseases. Although many medications are effective in combating chronic diseases, their full benefits are often not realized by the patients. Approximately 50% of patients do not adhere to long-term therapies,(2,3) and this percentage is much higher in developing countries.(3) A systematic review of anti-diabetic therapies found wide-ranging adherence rates between 36% to 93%.(4) This is of great concern when adherence to medication is critical to positive outcomes.

Factors contributing to poor medication adherence are myriad and include those that are related to patients, physicians and healthcare systems, so improving adherence requires a continuous and dynamic process.(3) Because of this complex matrix of factors, our knowledge of the underlying causes of poor medication adherence is still very limited. The collaboration with Medisafe offers the possibility to reveal new overall insights into patients’ behaviour, through data collected by Medisafe, which may contribute to improved chronic disease management in the future.

Brazil, Russia and Mexico are the first three countries where patients receiving Merck's primary care medicines will have access to a customized version of Medisafe. Globally, around 60 million patients with chronic conditions are estimated to be treated with Merck’s medications daily.

About Medisafe

Medisafe is a leading medication management and adherence solution co-owned by M Ventures. It has more than 4 million registered users, 4 billion patient data points and 140,000 apple store reviews with a 4.5-5 rating. It has received endorsements from the American Pharmacy Association, Journal of Medical Internet Research (JMIR), and Ranked Health. In addition, Medisafe is HIPPA (Health Insurance Portability and Accountability Act) compliant with the latest ISO 27001 security protection for patient data. In a recent study, its usage resulted in a 20% rise in prescription refills versus control (IMS Study).5 It is, therefore, not surprising that Medisafe has been named top app for medication management by November 2017 IQVIA (Quintiles IMS) report.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of € 15.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

1. Medisafe website. Available at: https://medisafe.com/research/ Accessed January 2018
2. Brown MT, Bussell JK. Medication Adherence: WHO Cares? Mayo Clin Proc. 2011 Apr; 86:304-314.
3. World Health Organization. Adherence to Long-Term Therapies. Evidence for Action Geneva: World Health Organization; 2003. Available at: http://whqlibdoc.who.int/publications/2003/9241545992.pdf Accessed January 2017.
4. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004; 27:1218-1224.
5. Medisafe website. Available at: https://medisafe.com/research/case-study-medisafe-platform-app-increase-medication-adherence/ Accessed January 2018.

Most Popular Now

NHS Staff Punished as 500,000 Rely on Wh…

WhatsApp, Facebook Messenger and other unauthorised instant messaging (IM) apps are being used by approximately 500,000 NHS staff at work, as a growing number turn to consumer tools to communicate...

Call for Abstracts: European Telemedicin…

27 - 29 May 2018, Sitges, Barcelona, Spain. The European Telemedicine Conference 2018 (ETC18) is an interdisciplinary forum for healthcare professionals, directors, managers, and researchers with the intent of bringing together...

conhIT 2018: The stage is Set for Dialog…

17 - 19 April 2018, Berlin, Germany. Finding out about and supporting all aspects of the digital transformation of the healthcare system: that is what this year's conhIT, Europe's largest event...

Smartphone 'Scores' can Help Doctors Tra…

Parkinson's disease, a progressive brain disorder, is often tough to treat effectively because symptoms, such as tremors and walking difficulties, can vary dramatically over a period of days, or even...

Focus on the Digital Transformation - A …

17 - 19 April 2018, Berlin, Germany. How is the digitalisation of the healthcare system affecting the relationship between patients and doctors? What new innovations and solutions does the health IT...

Portable Device Detects Severe Stroke in…

A new device worn like a visor can detect emergent large-vessel occlusion in patients with suspected stroke with 92 percent accuracy, report clinical investigators at the Medical University of South...

Imitation is the Most Sincere Form of Fl…

For every two mobile apps released, one is a clone of an existing app. However, new research published in the INFORMS journal Information Systems Research shows the success of the...

Merck Partners with Medisafe to Help Imp…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication intake and adhere to prescribed treatment regimens...

Philips Research-led Big Data Consortium…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, together with its consortium partners, today announced that it has received funding from the EU's Horizon 2020 program...

Smartphone App Performs Better than Trad…

A smartphone application using the phone's camera function performed better than traditional physical examination to assess blood flow in a wrist artery for patients undergoing coronary angiography, according to a...

Deep Learning Transforms Smartphone Micr…

Researchers at the UCLA Samueli School of Engineering have demonstrated that deep learning, a powerful form of artificial intelligence, can discern and enhance microscopic details in photos taken by smartphones...